Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 1.00 |
| ▸ | CNR1 | P21554 | 12/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3688359 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL14699456 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL29647952 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL31545228 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL10655727 | 0.90 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL10655723 | 0.90 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11199629 | 0.90 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL17388420 | 0.88 | CNR2 (0.78) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL17388422 | 0.88 | CNR2 (0.78) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL31545820 | 0.87 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | claimed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG R | 2008-05-08 | — | — | US | disclosed |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG R | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885NR1I2 658/4885 |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885NR1I2 658/4885 |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CNR1, DHCR24, CNR2 | CNR2 3/4885CNR1 1/4885NR1I2 460/4885 |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | CNR1, CNR2, ICOS | CNR2 2/4885CNR1 1/4885NR1I2 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.